Oncolytic virus in gliomas: a review of human clinical investigations

被引：36

作者：

Carpenter, A. B. ^{[1
]}

Carpenter, A. M. ^{[2
]}

Aiken, R. ^{[3
]}

Hanft, S. ^{[4
]}

机构：

[1] Georgetown Univ, Sch Med, 3900 Reservoir Rd NW, Washington, DC 20007 USA

[2] Rutgers New Jersey Med Sch, Neurol Inst New Jersey, Dept Neurol Surg, Newark, NJ USA

[3] Atlantic Healthcare, Gerald J Glasser Brain Tumor Ctr, Summit, NJ USA

[4] New York Med Coll, Westchester Med Ctr, Dept Neurol Surg, Valhalla, NY 10595 USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷 / 08期

关键词：

glioma; oncolytic virus; immunotherapy; NEWCASTLE-DISEASE VIRUS; RECURRENT MALIGNANT GLIOMAS; HIGH-GRADE GLIOMA; MUTANT; 1716; TRIAL; GLIOBLASTOMA; ADENOVIRUS; CANCER; G207; REPLICATION;

D O I：

10.1016/j.annonc.2021.03.197

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.

引用

页码：968 / 982

页数：15

共 81 条

[1] Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients [J].

Bah, Eugene S. ;

Nace, Rebecca A. ;

Peng, Kah Whye ;

Munoz-Alia, Miguel Angel ;

Russell, Stephen J. .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) :2057-2067

[2] Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo [J].

Bai, Yang ;

Chen, Yong ;

Hong, Xinyu ;

Liu, Xinrui ;

Su, Xing ;

Li, Shanji ;

Dong, Xuechao ;

Zhao, Gang ;

Li, Yunqian .

SCIENTIFIC REPORTS, 2018, 8

[3] Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus-1 G207 in Pediatric Malignant Supratentorial Brain Tumors [J].

Bernstock, Joshua D. ;

Wright, Zachary ;

Bag, Asim K. ;

Gessler, Florian ;

Gillespie, George Yancey ;

Markert, James M. ;

Friedman, Gregory K. ;

Johnston, James M. .

WORLD NEUROSURGERY, 2019, 122 :E1592-E1598

[4] H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future [J].

Bretscher, Clemens ;

Marchini, Antonio .

VIRUSES-BASEL, 2019, 11 (06)

[5] To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses [J].

Cassady, Kevin A. ;

Haworth, Kellie B. ;

Jackson, Josh ;

Markert, James M. ;

Cripe, Timothy P. .

VIRUSES-BASEL, 2016, 8 (02)

[6] Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma [J].

Chesney, Jason ;

Puzanov, Igor ;

Collichio, Frances ;

Singh, Parminder ;

Milhem, Mohammed M. ;

Glaspy, John ;

Hamid, Omid ;

Ross, Merrick ;

Friedlander, Philip ;

Garbe, Claus ;

Logan, Theodore F. ;

Hauschild, Axel ;

Lebbe, Celeste ;

Chen, Lisa ;

Kim, Jenny J. ;

Gansert, Jennifer ;

Andtbacka, Robert H. I. ;

Kaufman, Howard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1658-+

[7] Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? [J].

Chiocca, E. Antonio ;

Nassiri, Farshad ;

Wang, Justin ;

Peruzzi, Pierpaolo ;

Zadeh, Gelareh .

NEURO-ONCOLOGY, 2019, 21 (01) :14-25

[8] A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting [J].

Chiocca, EA ;

Abbed, KM ;

Tatter, S ;

Louis, DN ;

Hochberg, FH ;

Barker, F ;

Kracher, J ;

Grossman, SA ;

Fisher, JD ;

Carson, K ;

Rosenblum, M ;

Mikkelsen, T ;

Olson, J ;

Markert, J ;

Rosenfeld, S ;

Nabors, LB ;

Brem, S ;

Phuphanich, S ;

Freeman, S ;

Kaplan, R ;

Zwiebel, J .

MOLECULAR THERAPY, 2004, 10 (05) :958-966

[9] Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].

Cloughesy, Timothy F. ;

Mochizuki, Aaron Y. ;

Orpilla, Joey R. ;

Hugo, Willy ;

Lee, Alexander H. ;

Davidson, Tom B. ;

Wang, Anthony C. ;

Ellingson, Benjamin M. ;

Rytlewski, Julie A. ;

Sanders, Catherine M. ;

Kawaguchi, Eric S. ;

Du, Lin ;

Li, Gang ;

Yong, William H. ;

Gaffey, Sarah C. ;

Cohen, Adam L. ;

Mellinghoff, Ingo K. ;

Lee, Eudocia Q. ;

Reardon, David A. ;

O'Brien, Barbara J. ;

Butowski, Nicholas A. ;

Nghiemphu, Phioanh L. ;

Clarke, Jennifer L. ;

Arrillaga-Romany, Isabel C. ;

Colman, Howard ;

Kaley, Thomas J. ;

De Groot, John F. ;

Liau, Linda M. ;

Wen, Patrick Y. ;

Prins, Robert M. .

NATURE MEDICINE, 2019, 25 (03) :477-+

[10] Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma [J].

Csatary, LK ;

Bakács, T .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1588-1589

← 1 2 3 4 5 6 7 8 9 →